a CLINICAL Experience
Simply put, a diagnosis is described as “clinical,” it means this: It’s based on expert observation and pattern recognition, not a single test.
For Parkinson’s, there is no blood test, scan, or lab result that can definitively confirm the diagnosis on its own.
Instead, a clinician, usually a Neurologist use:
A Clear, Human Guide to Parkinson’s Disease
Diagnosis is rarely made from a single moment. It’s based on patterns that unfold over time. One visit starts the conversation.
Your first exam is about observation and history. Understanding this process helps you walk in prepared, more at ease.
Think of it like this: Imaging, scan, or lab result is only the snapshot. The clinical diagnosis is the movie.
These observations often reveal patterns that structured tests alone can’t, and help guide the rest of the exam.
The exam should include a review of your medical history, along with your symptoms and how they’ve changed over time. When symptoms began, how they’ve progressed, and what makes them better or worse all provide important context and help the neurologist interpret what they see during the exam.
Importantly, this isn’t about how fast you move at the start, it’s about how movement changes over time. These patterns help distinguish Parkinson’s-related Bradykinesia from normal slowing, stiffness, or weakness.
The Neurologist may repeat these movements or ask you to perform a simple task with the opposite limb (such as opening and closing your hand) to see if rigidity becomes more apparent, a phenomenon known as Activation.
IImportantly, rigidity in Parkinson’s is different from spasticity -speed-dependent stiffness (or joint problems). Recognizing this difference helps a Neurologist distinguish Parkinson’s from other neurological or musculoskeletal conditions.
The Neurologist is assessing the timing, pattern, and distribution of the tremor. Parkinson’s tremor most often appears at rest and may decrease or temporarily disappear with movement, while other tremor types, such as essential tremor, are more prominent during action or posture.
These details help distinguish Parkinson’s-related tremor from essential tremor and other neurologic conditions. Importantly, not everyone with Parkinson’s has a visible tremor, and the absence of tremor does not rule out the disease.
These non-motor features provide critical context and help support the diagnosis, even when motor symptoms are mild. Together with the movement exam, they help the neurologist identify a consistent pattern rather than relying on any single finding.
A movement-disorder Neurologist is not looking for one isolated sign. They are looking for a pattern of features that fit together, including:
Just as important is what doesn’t show up during the exam or on testing. Normal scans or lab results don’t rule out Parkinson’s, they often help confirm that symptoms aren’t being caused by something else.
For many people, diagnosis doesn’t happen in a single visit. It often unfolds over multiple appointments, as patterns become clearer and changes over time provide additional insight. This step-by-step approach is intentional, and it’s one of the reasons experience with Parkinson’s matters.
Blood testing doesn’t confirm Parkinson’s Disease. Instead, it helps rule out other possible causes of symptoms and guides clinicians toward the most accurate diagnosis.
LRRK2: the most common genetic cause of Parkinson’s worldwide
GBA: increases risk and may influence symptom progression
PARK2 (Parkin): often linked to younger-onset Parkinson’s
PINK1: associated with early-onset forms
SNCA: rare, but directly involved in Alpha-Synuclein production
PARK7 (DJ-1): helps protect brain cells from stress and damage; rare cause of early-onset Parkinson’s
VPS35: involved in the cell’s protein recycling system; mutations can contribute to Parkinson’s, typically adult-onset
These panels focus only on genes with established relevance, rather than sequencing everything.
A reliable biomarker could allow earlier detection, more accurate diagnosis, and better tracking of Parkinson’s progression. It could even accelerate the development of treatments designed to slow the disease itself. So what exactly is a biomarker?
A Biomarker is a measurable substance or characteristic in the body that provides information about health or disease.
Example:
High cholesterol is a Biomarker that signals increased risk for heart disease.
Biomarkers can be found in blood, urine, cerebrospinal fluid, skin, or tissue.
For Parkinson’s, Biomarker research is still evolving, but it is becoming increasingly important for improving diagnosis, research, and clinical trials.
Two emerging tests you may hear about are the Alpha-Synuclein Seed Amplification Assay (SAA) and the Syn-One Skin Biopsy Test. Both look for abnormal forms of the protein Alpha-Synuclein, a key protein involved in Parkinson’s Disease.
As noted earlier, Parkinson’s is diagnosed through clinical evaluation, not a single test. Biomarkers like SAA and Syn-One are promising tools that may strengthen diagnostic confidence and advance research, but they are supporting pieces of the puzzle, not standalone answers.